Scopus BioPharma (SCPS) Financial Statements
Scopus BioPharma Financial Overview
Scopus BioPharma's market cap is currently $16.83K. The company's EPS TTM is $-0.32; its P/E ratio is 0.00; Scopus BioPharma is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -11.71M | $ -27.63M | $ -10.16M | $ -2.69M | $ -685.96K |
| EBITDA | $ -11.71M | $ -26.18M | $ -10.15M | $ -2.69M | $ -685.96K |
| Net Income | $ -11.61M | $ -27.73M | $ -11.57M | $ -2.69M | $ -685.96K |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 124.58K | $ 7.94M | $ 1.83M | $ 36.75K | $ 1.66K |
| Total Assets | $ 392.26K | $ 8.19M | $ 1.97M | $ 771.68K | $ 132.64K |
| Total Debt | $ 0.00 | $ 0.00 | $ 2.28M | $ 0.00 | $ 0.00 |
| Net Debt | $ -124.58K | $ -7.94M | $ 451.63K | $ -36.75K | $ -1.66K |
| Total Liabilities | $ 7.45M | $ 4.17M | $ 3.81M | $ 854.54K | $ 137.96K |
| Stockholders' Equity | $ -6.56M | $ 4.02M | $ -1.83M | $ -82.86K | $ -5.33K |
| Cash Flow | |||||
| Free Cash Flow | $ -8.13M | $ -11.43M | $ -2.53M | $ -2.12M | $ -747.32K |
| Operating Cash Flow | $ -8.13M | $ -11.42M | $ -2.53M | $ -2.12M | $ -747.32K |
| Investing Cash Flow | $ -1.55K | $ -2.00K | $ 0.00 | $ -4.25K | $ 0.00 |
| Financing Cash Flow | $ 241.94K | $ 17.56M | $ 4.35M | $ 2.18M | $ 597.63K |
Currency in USD